News from ardelyx A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 03, 2020, 08:00 ET Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


Jun 30, 2020, 08:00 ET Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney...


Jun 15, 2020, 08:00 ET Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people...


Jun 09, 2020, 20:45 ET Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


Jun 08, 2020, 16:01 ET Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


May 26, 2020, 09:00 ET Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


May 21, 2020, 17:23 ET Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


May 18, 2020, 16:01 ET Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


May 07, 2020, 16:02 ET Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


Mar 16, 2020, 09:00 ET Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors

Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


Mar 06, 2020, 16:02 ET Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for ...


Feb 26, 2020, 08:00 ET Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the Cowen and Company...


Feb 19, 2020, 08:00 ET Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the 9th Annual SVB...


Dec 04, 2019, 23:32 ET Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


Dec 04, 2019, 16:56 ET Ardelyx Announces Proposed Public Offering of Common Stock

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


Dec 03, 2019, 07:25 ET Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people...


Dec 02, 2019, 16:01 ET Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study

Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people...


Nov 26, 2019, 16:00 ET Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people...


Nov 25, 2019, 18:00 ET Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people...


Nov 06, 2019, 16:05 ET Ardelyx Announces Presentation at Kidney Week 2019

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people...


Nov 06, 2019, 16:02 ET Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for ...


Oct 10, 2019, 16:00 ET Ardelyx to Host Analyst Day in New York

Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an Analyst Day on Thursday, Oct. 17, 2019, from 7:30 a.m. to 11:00 a.m. ET in New...


Sep 17, 2019, 16:01 ET Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


Sep 12, 2019, 15:13 ET Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment...


Sep 03, 2019, 08:00 ET Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people...